Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sezary Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44130   clinical trials with a EudraCT protocol, of which   7324   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Sezary Syndrome. Displaying page 1 of 1.
    EudraCT Number: 2019-004566-17 Sponsor Protocol Number: EORTC-1820-CLTF Start Date*: 2021-07-22
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma
    Medical condition: Cutaneous T-cell lymphoma (Mycosis Fungoides (MF) and Sézary Syndrome (SS))
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028502 Mycosis fungoides refractory LLT
    22.0 100000004864 10028504 Mycosis fungoides stage II LLT
    22.0 100000004864 10028503 Mycosis fungoides stage I LLT
    22.0 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    22.0 100000004864 10028511 Mycosis fungoides/Sezary syndrome refractory LLT
    22.0 100000004864 10028512 Mycosis fungoides/Sezary syndrome stage I LLT
    22.0 100000004864 10028513 Mycosis fungoides/Sezary syndrome stage II LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Ongoing) GR (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002093-60 Sponsor Protocol Number: BCX1777-203 Start Date*: 2007-10-05
    Sponsor Name:BioCryst Pharmaceuticals, Inc.
    Full Title: Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma
    Medical condition: Primary cutaneous T-cell lymphomas (CTCLs)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) FI (Completed) IT (Completed) ES (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011020-65 Sponsor Protocol Number: EORTC21081 Start Date*: 2011-02-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.
    Medical condition: Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) AT (Completed) FI (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000807-99 Sponsor Protocol Number: 4SC-201-6-2015 Start Date*: 2016-09-15
    Sponsor Name:4SC AG
    Full Title: A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ...
    Medical condition: Advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) NL (Prematurely Ended) ES (Ongoing) AT (Ongoing) BE (Completed) PL (Completed) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004537-20 Sponsor Protocol Number: 0761-016 Start Date*: 2021-07-22
    Sponsor Name:Kyowa Kirin Inc.
    Full Title: Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
    Medical condition: Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) - Mycosis fungoides and Sezary syndrome
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028510 Mycosis fungoides/Sezary syndrome recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003680-35 Sponsor Protocol Number: 1652-CLTF Start Date*: 2019-01-31
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)
    Medical condition: Subtypes of Cutaneous T cell ltymphoma (CTCL): Mycosis Fungoides (MF) and Sézary Syndrome (SS)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028508 Mycosis fungoides/Sezary syndrome LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028483 Mycosis fungoides LLT
    20.0 10005329 - Blood and lymphatic system disorders 10028484 Mycoses fungoides HLT
    20.0 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10040785 - Skin and subcutaneous tissue disorders 10042356 Skin and subcutaneous conditions NEC HLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040790 Skin and subcutaneous tissue disorders NEC HLGT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) AT (Completed) GR (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-003353-24 Sponsor Protocol Number: Hx-CD4-110 Start Date*: 2007-04-25
    Sponsor Name:TenX Biopharma, Inc.,
    Full Title: Open-label, Dose escalation, followed by Open-label, Single Arm, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides (stage IB-I...
    Medical condition: Refractory Mycosis Fungoides (stage IB-IVB) and Sézary Syndrome. The study population will be patients who are refractory to or intolerant to at least two prior therapies, one being Targretin, the...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028502 Mycosis fungoides refractory LLT
    9.1 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002692-16 Sponsor Protocol Number: APL-B-012-02 Start Date*: 2004-10-27
    Sponsor Name:PharmaMar SA unipersonal
    Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms.
    Medical condition: Non-Hodgkin’s Lymphomas (NHLs) relapsing or refractory
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000924-11 Sponsor Protocol Number: CTCL Start Date*: 2015-06-17
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty Mannheim represented by the chancellor
    Full Title: Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.
    Medical condition: Cutaneous T cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003286-28 Sponsor Protocol Number: CA209-436 Start Date*: 2016-04-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression
    Medical condition: Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10029606 Non-Hodgkin's lymphomas transformed recurrent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000821-23 Sponsor Protocol Number: DSHNHL2006-1B/ACT-2 Start Date*: 2007-08-10
    Sponsor Name:University Medicine Goettingen
    Full Title: A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubi...
    Medical condition: Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 years ICD classification codes : ICD-O 9702/3; 9717/3; 9716/3; 9708/3; 9705/3; 9714/3
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10025632 Malignant lymphoma LLT
    17.1 100000004864 10002464 Angiomimmunoblastic (AILD, LgX (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) NL (Completed) FR (Completed) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005039-34 Sponsor Protocol Number: ASTX660-01 Start Date*: 2018-02-05
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
    Medical condition: Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinoma; cohort 2:Relapsed or refractory diffuse large B-cell ly...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10011677 Cutaneous T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) FR (Ongoing) HU (Ongoing) ES (Ongoing) BE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA